rMark Bio provides a proprietary deep learning platform that analyzes global healthcare data alongside internal clinical research data to optimize partnership and engagement strategies across a product's lifecycle. The platform is used to align real-time business strategies between R&D, product, commercialization, and external teams, reducing time and cost of data analysis. Customers include pharmaceutical companies, academic institutions, medical device companies, and investment firms; the company provides AI services to the top 20 pharmaceutical companies globally. rMark Bio has partnered with industry-leading technology and healthcare organizations. Led by Co-founder and CEO Jason Smith, the company is headquartered in Chicago, IL. It intends to use the new funding to continue expanding its global presence. rMark Bio offers Fabric, an end-to-end AI solution designed to accelerate innovation and scientific discoveries for life sciences companies. Fabric automates aggregation and preparation of data for machine learning, trains neural networks to analyze data and surface scientific insights, and exposes APIs to integrate those insights into existing applications. The platform is trained to understand petabytes of unstructured text, videos, voice, proteomics, genomic and free-form data and integrates with business apps such as Microsoft, Salesforce and Veeva as well as third-party sources including IQVIA and Symphony Health. Fabric is currently licensed and deployed in several top-20 pharmaceutical companies. Founded in 2015 by Jason M. Smith and Lev Becker, rMark Bio operates from Chicago and Seattle. The company plans to use recent funding to expand its market presence, hire key personnel and support its transition to a new headquarters at 440 N. Wells in Chicago.

Total raised

$2M

Funding rounds

2

Latest round

Seed

Latest activity

Feb 2019